ArticleCancer control : journal of the Moffitt Cancer Center

Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I.

Thanh Ha Vu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.